The marketing research of the Ukrainian market of drugs for the treatment of arthritis
Keywords:rheumatoid arthritis, marketing analysis, pharmaceutical market, gel
Rheumatoid arthritis (RA) is a chronic systematic disease of the connective tissue with peripheral joints damage and characteristic non-arterial effects. Rheumatic diseases affect the national economy, lead to considerable expenses for their treatment and reduce the quality of the patients’ life.
Aim. To study drugs used for the treatment of arthritis at the Ukrainian pharmaceutical market, determine the number of the domestic and imported producers.
Materials and methods. The analysis of the drug assortment was conducted in accordance with the State Register of Drugs of Ukraine and ATC-classification of the WHO. The sources of information used were Compendium 2016 – Drugs, and a Software Complex, a weekly journal “Pharmacy online”.
Results and discussion. It has been determined that the leading position of producers of drugs for the treatment of RA belongs to national manufacturers, and there is also a significant market share in manufacturers from Germany, Switzerland and Israel. By the pharmacological action the most common group (26 %) is presented by anti-inflammatory and anti-rheumatic drugs; 25 % of foreign and domestic drugs are antiviral drugs; 19 % are other drugs used in pathology of the locomotor system. The majority group of medicines consists of tablets, capsules and injectable dosage forms.
Conclusions. According to the ATC-classification data there are approximately 60 drugs presented at the pharmaceutical market of Ukraine for the treatment of rheumatic diseases. This market segment includes different pharmacotherapeutic groups, a wide range of manufacturing countries and pharmaceutical companies. However, there is no original combined gel of the complex national production at the pharmaceutical market of Ukraine.
Kovalenko, N. A., Supichenko, G. N., Leontev, V. N., Shutova, A. G., Kulinchik, A. I. (2010). Zhurnal Trudy BGTU, 1 (4).
Agarwal, S. K. (2011). Core Management Principles in Rheumatoid Arthritis to Help Guide Managed Care Professionals. Journal of Managed Care Pharmacy, 17 (9 Supp B), S03–S08. doi: 10.18553/jmcp.2011.17.s9–b.s03
Morozov, A. M., Yakovlieva, L. V., Bezditko, N. V. et al. (2013). Otsinka klinichnoi ta ekonomichnoi dotsilnosti vykorystannia likarskykh zasobiv u likuvalno–profilaktychnomu zakladi (suprovid formuliarnoi systemy). Kharkiv: Styl–Yzdat, 36.
Klimeš, J., Vocelka, M., Šedová, L., Doležal, T., Mlčoch, T., Petříková, A., Vlček, J. (2014). Medical and Productivity Costs of Rheumatoid Arthritis in The Czech Republic: Cost–of–Illness Study Based on Disease Severity. Value in Health Regional Issues, 4, 75–81. doi: 10.1016/j.vhri.2014.07.004
Gaujoux–Viala, C., Smolen, J. S., Landewe, R., Dougados, M., Kvien, T. K., Mola, E. M., Gossec, L. (2010). Current evidence for the management of rheumatoid arthritis with synthetic disease–modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 69 (6), 1004–1009. doi: 10.1136/ard.2009.127225
Nam, J. L., Winthrop, K. L., van Vollenhoven, R. F., Pavelka, K., Valesini, G., Hensor, E. M. A., Buch, M. H. (2010). Current evidence for the management of rheumatoid arthritis with biological disease–modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Annals of the Rheumatic Diseases, 69 (6), 976–986. doi: 10.1136/ard.2009.126573
Meier, F. M., Frerix, M., Hermann, W., Müller–Ladner, U. (2013). Current immunotherapy in rheumatoid arthritis. Immunotherapy, 5 (9), 955–974. doi: 10.2217/imt.13.94
8. Derzhavnyi reiestr likarskykh zasobiv Ukrainy. (2015). Kyiv: MOZ Ukrainy. Available at: http: // www. drlz.kiev.ua
Blikhar, V. Ye., Maltsev, V. I., Morozov, A. M., Parii, V. D., Stepanenko, A. V., Dumenko, T. M. (2012). Derzhavnyi formuliar likarskykh zasobiv. Kyiv, 4, 1159.
Kovalenko, V. N. (2015). Kompendium 2016 – lekarstvennye preparaty. Kiev: Morion, 1408.
Copyright (c) 2018 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).